RBC Capital maintains Pfizer at Sector Perform, raises price target to $28 from $25

What happened

RBC Capital maintained its Sector Perform rating on Pfizer and raised its price target to $28 from $25, a 12.0% increase. The article says the new target implies 6.7% downside from Pfizer’s November 3 closing price of $30.

Confirmed

Global impact / market context

The higher target signals RBC sees more value in Pfizer than before, but its stated target remains below the cited closing price. If investors use analyst targets to guide decisions, this mixed signal could shape demand for the shares, though it does not change Pfizer’s business or cash flows by itself.

Analyst inference

The article reports three other recent analyst targets, ranging from $28 to $33, with ratings of Neutral, Neutral, and Sector Outperform. RBC’s $28 target is at the low end of that range, indicating differing views among analysts rather than a shared outlook.

Confirmed

What to watch

1. Watch for any subsequent changes to RBC’s rating or target; the report gives no estimate of how the higher target would affect Pfizer’s revenue, costs, or cash available. Analyst inference
2. Compare future analyst targets and ratings with the cited $28–$33 range to see whether views converge or continue to differ; the article provides no later updates. Analyst inference
3. The stated $28 target implies 6.7% downside from the November 3 close of $30; any comparison should use the same reference date and price basis. Confirmed

Evidence

• Original source link unavailable